Latest Conference Articles

January 24th 2013, 8:31am

Gastrointestinal Cancers Symposium (ASCO GI)

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

January 23rd 2013, 1:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced esophagogastric adenocarcinoma who received docetaxel as a second-line therapy experienced a longer period of overall survival as well as a better quality of life compared with patients who received active symptom control.

January 23rd 2013, 1:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

December 11th 2012, 3:08pm

ASH Annual Meeting and Exposition

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

December 11th 2012, 1:44pm

ASH Annual Meeting and Exposition

Proposed federal budget cuts that could affect the National Institutes of Health, and thus hematology/oncology research, were highlighted as an area of concern during the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

December 11th 2012, 1:24pm

ASH Annual Meeting and Exposition

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

December 10th 2012, 2:16pm

San Antonio Breast Cancer Symposium

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

December 10th 2012, 9:57am

San Antonio Breast Cancer Symposium

Photos from the 35th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center, San Antonio, TX, from December 4-8, 2012.

December 10th 2012, 8:54am

ASH Annual Meeting and Exposition

Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance-including the stubborn T315I mutation-in all stages of CML and Ph+ ALL.

December 10th 2012, 7:24am

ASH Annual Meeting and Exposition

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

December 10th 2012, 7:00am

ASH Annual Meeting and Exposition

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.

December 9th 2012, 3:05pm

ASH Annual Meeting and Exposition

Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.

December 9th 2012, 2:18pm

ASH Annual Meeting and Exposition

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

December 9th 2012, 2:03pm

ASH Annual Meeting and Exposition

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

December 9th 2012, 8:21am

ASH Annual Meeting and Exposition

The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab.

December 9th 2012, 8:00am

ASH Annual Meeting and Exposition

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

December 8th 2012, 5:36pm

San Antonio Breast Cancer Symposium

The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."

December 8th 2012, 5:14pm

San Antonio Breast Cancer Symposium

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

December 8th 2012, 11:14am

ASH Annual Meeting and Exposition

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.

December 8th 2012, 9:26am

San Antonio Breast Cancer Symposium

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.